Last updated 2026-10-28
- Raised $500M convertible note, Nov 2020
- Raised $150M debt round, Nov 2020
- Raised $150M debt round, Feb 2018
Total raised
$965.0M
Last: Debt Financing 2024-05
Stage
Public
Founded
2000
Headcount
1,605
HQ
Baar, Switzerland
Sector
Health Tech & Life Sciences
About
NovoCure is a global oncology company focused on extending survival in aggressive forms of cancer through its proprietary Tumor Treating Fields (TTFields) therapy. TTFields therapy uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division. The company's commercialized products, including Optune Gio, Optune Lua, and Optune Pax, are approved in certain countries for the treatment of glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and locally advanced pancreatic cancer. NovoCure conducts research and development in Haifa, Israel, and has operations across North America, Europe, the Middle East, and Asia.
Funding history · 9 rounds · $965.0M total
9 events/rounds · $965.0M Total Funding: $165.0M in Public Equity, $800.0M in Debt
Nov 2020
Convertible Debt
$500.0M
EDGAR filing SEC-EDGAR 8-K
Nov 2020
Debt Financing
$150.0M
EDGAR filing SEC-EDGAR 8-K
Feb 2018
Debt Financing
$150.0M
EDGAR filing SEC-EDGAR 8-K
Oct 2015
Public Offering
$165.0M
prior (startupim db)
Jun 2015
2013
Sep 2009
★ Index Ventures★ Johnson & Johnson Innovation – JJDCPfizer IncJohnson & Johnson Development Corporation
Jan 2003
★ WFD Ventures LLC
Jan 2000
Offices
Baar, Switzerland · HQ / main office
Q&A
- What is NovoCure's primary focus?
- NovoCure is a global oncology company focused on extending survival in aggressive forms of cancer through its proprietary Tumor Treating Fields (TTFields) therapy.
- Where is NovoCure's headquarters located?
- NovoCure's headquarters is located in Baar, Switzerland.
- What is NovoCure's current employee count?
- NovoCure has over 500 employees.
- What was NovoCure's most recent funding round?
- NovoCure completed a Debt Financing round in May 2024, raising $400,000,000.
- Which investors participated in NovoCure's A Round?
- NovoCure's A Round in September 2009 included Index Ventures and Johnson & Johnson Innovation – JJDC as lead investors.
- What is NovoCure's total amount raised in funding?
- NovoCure has raised a total of $965,000,000 USD.
- What are some of NovoCure's commercialized products?
- NovoCure's commercialized products include Optune Gio, Optune Lua, and Optune Pax, which are approved in certain countries for the treatment of glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and locally advanced pancreatic cancer.
- Where does NovoCure conduct its research and development?
- NovoCure conducts research and development in Haifa, Israel.
Team · 27
Ashley Cordova
Chief Executive Officer
Frank Leonard
Executive Vice President and President, Novocure Oncology
Barak Ben-Arye
General Counsel
Mukund Paravasthu
Chief Operating Officer
Uri Weinberg
Chief Medical & Innovation Officer
Christoph Brackmann
Chief Financial Officer
Michael Puri
Chief Human Resources Officer
Nicolas Leupin
Chief Medical Officer
Moshe Giladi
Chief Science Officer
Jonathan Tepe
Vice President, Global Revenue Operations
Kimberly Burke
Vice President, Deputy General Counsel
Jeff Bamonte
Area Vice President, Sales & Customer Engagement
Justin Kelly
Regional Vice President, Health Policy
Laura Benson
VP Medical Affairs
Tania Chander
Vice President, US Medical Affairs
Kathleen Bachrach
Vice President, Global Tax
William F. Doyle
Executive Chairman
Asaf Danziger
Board Member
William A. Vernon
Lead Independent Director
Jeryl Hilleman
Board Member
David T. Hung
Board Member
Kinyip Gabriel Leung
Board Member
Martin J. Madden
Board Member
Allyson J. Ocean
Board Member
Timothy J. Scannell
Board Member
Kristin Stafford
Board Member
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
Patents
Tags
cell-therapycancernon-invasivemedical-technologieschemotherapyoncologypharmaceuticalstreatmentswearable
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | novocure.com |
|---|---|
| linkedin.com/company/105770 | |
| Wikipedia | he.wikipedia.org/wiki/%D7%A0%D7%95%D7%91%D7%95%D7%A7%D7%99%D |
| Wikidata | wikidata.org/wiki/Q30267502 |
Identifiers & details
| Legal name | NovoCure Limited |
|---|---|
| Founded | 2000 |
| Employees (exact) | 1605 |
| Wikidata QID | Q30267502 |
Radar intelligence
Patents
| EPO | 375 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
App Store
| App | Rating | Ratings |
|---|---|---|
| MyNovocure | 3.42857 |
Web history (Wayback)
| Domain | novocure.com |
|---|
Wikidata
| QID | Q30267502 |
|---|
Certificate / subdomain footprint
| Subdomains | 87 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512768003 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1999-04-15 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 1 — annual_report (1) |
| Registered address | חת נחום 5 טירת כרמל |
Recent registry events
| Date | Event |
|---|---|
| 2026-07-15 | דו~ח שנתי-עדכון כתובת |